Diffuse Large B Cell Lymphoma New Protocol: Glofitamab with R-CHOP for High-Risk DLBCL Ulas D. Bayraktar, MD 2025-09-08
Non-Small Cell Lung Cancer New Indication: Neoadjuvant Osimertinib with/without Chemo for NSCLC Ulas D. Bayraktar, MD 2025-09-08
Hodgkin Lymphoma New Protocol: Brentuximab – ECADD Chemo for Hodgkin Lymphoma Ulas D. Bayraktar, MD 2025-09-08
Pancreatic Cancer New Reference: Advanced Pancreatic Cancer Protocols Ulas D. Bayraktar, MD 2025-09-08
Prostate Cancer New REference: Talazoparib and Enzalutamide for HRR-Deficient Prostate Cancer Ulas D. Bayraktar, MD 2025-09-08
Renal Cell Carcinoma New Indication: Bevacizumab and Erlotinib for Papillary Renal Cell Carcinoma Ulas D. Bayraktar, MD 2025-09-08
Chronic Lymphocytic Leukemia New Reference: MRD-Guided CLL Treatment Ulas D. Bayraktar, MD 2025-09-08
GastroEsophageal Cancer New Protocol: Perioperative Durvalumab with FLOT in Gastric Cancer Ulas D. Bayraktar, MD 2025-09-08
Non-Small Cell Lung Cancer New Reference: Neoadjuvant Nivolumab for NSCLC Ulas D. Bayraktar, MD 2025-09-08
Head and Neck Cancer New Indication: Periop Pembrolizumab for Head and Neck Cancer Ulas D. Bayraktar, MD 2025-09-08
